Graves' Disease: Autoimmune Hyperthyroidism Explained

An Immune System Attacking the Wrong Switch

Graves' disease accounts for 80 percent of all hyperthyroidism cases in iodine-sufficient countries and affects approximately 3 percent of women and 0.5 percent of men over their lifetimes. The mechanism is unusually specific: the immune system generates thyroid-stimulating immunoglobulins (TSI) — autoantibodies that bind to and chronically activate the TSH receptor on thyroid follicular cells. Unlike TSH, which surges briefly and then withdraws as the pituitary responds to rising thyroid hormone levels, TSI binds without triggering the normal feedback shutdown. The thyroid gland receives a permanent, unregulated activation signal.

The Autoimmune Mechanism

TSH receptors (TSHRs) are expressed almost exclusively on thyroid follicular cells. Under normal conditions, TSH from the pituitary binds these receptors transiently, stimulating synthesis and release of thyroxine (T4) and triiodothyronine (T3). In Graves' disease, B lymphocytes produce TSI (also called thyrotropin receptor antibodies, TRAbs) that bind the TSHR with high affinity. This binding:

• Stimulates thyroid hormone overproduction: T3 and T4 levels rise far above normal, suppressing TSH to undetectable levels (<0.01 mIU/L). The lab pattern — low TSH, high free T4 and T3 — is the diagnostic fingerprint.
• Induces thyroid gland growth: Chronic receptor stimulation causes diffuse, symmetrical thyroid enlargement (goiter) in approximately 70 percent of patients.
• Drives extrathyroidal manifestations: TSHRs are also expressed in orbital fibroblasts and pretibial skin, explaining Graves' ophthalmopathy and (rarely) pretibial myxedema.

TRAb positivity is found in 97–99 percent of Graves' patients and is the most specific diagnostic test available. Other causes of hyperthyroidism — toxic multinodular goiter, toxic adenoma, thyroiditis — do not produce TRAbs.

Clinical Features

Excess thyroid hormone affects nearly every organ system. Metabolic rate increases, generating heat (heat intolerance, sweating), accelerating heart rate (resting tachycardia, palpitations, atrial fibrillation in 10–15 percent of cases), and driving weight loss despite increased appetite. Sympathetic nervous system hyperactivation produces tremor, anxiety, and insomnia. Prolonged hyperthyroidism causes bone loss: thyroid hormone stimulates osteoclast activity, reducing bone mineral density by 10–15 percent in untreated cases over two years.

Thyroid Storm: A Medical Emergency

Thyroid storm is a life-threatening exacerbation of thyrotoxicosis with a mortality rate of 10–30 percent even with treatment. It is precipitated by physiological stressors in patients with uncontrolled or undiagnosed Graves' disease: surgery, infection, trauma, or iodine contrast agents. Criteria include temperature above 38.5°C, heart rate above 130 beats per minute, and features of altered mental status or cardiac decompensation. Treatment requires ICU-level care: propylthiouracil (PTU) to block hormone synthesis AND block peripheral T4-to-T3 conversion, potassium iodide (one hour after PTU, to prevent iodine from fueling new hormone synthesis), corticosteroids, beta-blockers, and active cooling.

Treatment Options Compared

Three definitive treatments exist for Graves' disease, each with distinct advantages and limitations:

Methimazole is preferred over PTU for most non-pregnant adults due to once-daily dosing and lower hepatotoxicity risk. PTU is used in the first trimester of pregnancy because methimazole is associated with rare fetal aplasia cutis and choanal atresia. The choice between RAI and surgery for definitive therapy depends on patient age, ophthalmopathy status, goiter size, and patient preference.

Graves' Ophthalmopathy

Approximately 25 percent of Graves' patients develop clinically significant ophthalmopathy; severe cases occur in 3–5 percent. TSHRs in orbital fibroblasts respond to circulating TRAbs by proliferating and producing hyaluronic acid, causing orbital fat and extraocular muscle volume to expand within the fixed orbital bony socket. The result is proptosis (eye bulging), diplopia, corneal exposure, and in severe cases, optic nerve compression threatening vision.

Smoking is the strongest modifiable risk factor — smokers have a fourfold higher risk of developing ophthalmopathy and respond poorly to treatment. RAI can worsen ophthalmopathy in active eye disease; prophylactic selenium supplementation (200 mcg daily for six months) has been shown in a 2011 NEJM trial to significantly improve mild-to-moderate cases. Severe ophthalmopathy is treated with intravenous glucocorticoids or orbital decompression surgery.

Monitoring and Long-Term Outlook

After achieving biochemical control, TRAb levels are measured to predict remission likelihood. Persistently elevated TRAbs at 12–18 months predict relapse after stopping antithyroid drugs; patients with normalized TRAbs have a 50–60 percent chance of sustained remission. Pregnancy substantially worsens Graves' disease autoimmunity — close monitoring of TRAb levels in the third trimester is essential, as high maternal TRAbs cross the placenta and can cause neonatal thyrotoxicosis.

This article is for informational purposes only. Consult a qualified healthcare professional.